74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Edwards Lifesciences Corp
Closed
SectorHealthcare
73.07 1.36
Overview
Share price change
24h
Min
70.56
Max
73.22
Income | -2.7B 346M |
|---|---|
Sales | 31M 1.4B |
P/E Sector Avg | 30.714 63.778 |
EPS | 0.59 |
Profit margin | 24.989 |
Employees | 15,800 |
EBITDA | 55M 484M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +7.62% upside |
Next Earnings | 23 Apr 2025 |
|---|
Market Cap | -1.1B 42B |
|---|---|
Previous open | 71.71 |
Previous close | 73.07 |
News Sentiment
By Acuity
62%
38%
340 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Edwards Lifesciences Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Edwards Lifesciences Corp Forecast
Price Target
By TipRanks
7.62% upside
12 Months Forecast
Average 77.54 USD 7.62%
High 90 USD
Low 60 USD
Based on 19 Wall Street analysts offering 12 month price targets forEdwards Lifesciences Corp - Dist in the last 3 months.
Sentiment
By Acuity
340 / 386 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
